Nanoscan (Human Serum Albumin)

• Nanoscan (human serum albumin) is used as a plasma volume expander in conditions characterized by low oncotic pressure or protein loss.
• Hypoalbuminemia: restores serum albumin levels and improves oncotic pressure.
• Burn injuries: provides volume expansion and protein replacement in severe burns.
• Major surgery: maintains circulatory volume and supports hemodynamic stability.
• Chronic liver disease: corrects low albumin concentrations in patients with hepatic insufficiency.

• Human serum albumin acts as a natural plasma protein that contributes to colloid osmotic pressure, helping retain fluid within the vascular compartment. When administered intravenously, it expands intravascular volume, binds and transports endogenous substances (e.g., hormones, fatty acids, drugs), and serves as a carrier for various metabolites, thereby supporting circulatory stability and tissue perfusion.

Adverse reactions may occur with intravenous human serum albumin administration.

Common Side Effects

• Fever or chills
• Mild hypotension
• Headache
• Nausea or vomiting
• Rash or urticaria
• Transient hypertension

Serious or Rare Side Effects

• Anaphylactic or severe allergic reaction
• Volume overload leading to pulmonary edema
• Hemolysis
• Acute kidney injury
• Transmission of infectious agents (theoretical risk)
• Severe hypotension or shock

Human serum albumin should be used with attention to patient‑specific factors and monitoring.

• Allergy assessment: verify no known hypersensitivity to albumin or blood products.
• Volume status: evaluate for risk of fluid overload, especially in cardiac or renal failure.
• Cardiac monitoring: observe for signs of congestive heart failure during infusion.
• Renal function: adjust infusion rate in patients with impaired kidney function.
• Co‑administration with diuretics: monitor fluid balance closely.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Albumin can influence the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Concurrent volume expanders: may precipitate fluid overload.
• High‑dose diuretics: increase risk of hypovolemia.
• Certain anticoagulants (e.g., warfarin): altered plasma protein binding may affect anticoagulant effect.

Moderate Interactions (Monitor Closely)

• Drugs highly bound to albumin (e.g., phenytoin, valproic acid): monitor serum levels.
• Antibiotics such as penicillins: potential displacement leading to increased free drug.
• ACE inhibitors or ARBs: watch for additive hypotensive effects.